BA
DNLI icon

Bellwether Advisors’s Denali Therapeutics DNLI Stock Holding History

Bellwether Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-86
Closed -$6K – 561
2021
Q2 		$6K Sell
86
-50
-37% -$3.09K ﹤0.01% 297
2021
Q1 		$7K Buy
+136
New +$9.1K ﹤0.01% 275

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bellwether Advisors's DNLI Position: Q3 2021 in Review

Bellwether Advisors sold out of Denali Therapeutics (DNLI) in Q3 2021, closing a stake of 86 shares — an estimated $6K sold.

Bellwether Advisors first reported a position in DNLI in Q1 2021 and held it in 2 quarters. The position peaked at $7K in Q1 2021. 214 funds tracked by Wall St. Rank hold DNLI as of Q3 2021.

  • Bellwether Advisors reported no remaining Denali Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Bellwether Advisors sold 86 Denali Therapeutics shares in Q3 2021, an estimated $6K.
  • Bellwether Advisors first reported a position in Denali Therapeutics in Q1 2021 and held it in 2 quarters.
  • Bellwether Advisors's Denali Therapeutics position peaked at $7K in Q1 2021.
  • 214 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2021.

Based on Bellwether Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.